Could an antimalarial drug speed recovery from babesiosis?
NCT ID NCT06207370
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding the antimalarial drug tafenoquine to standard care helps hospitalized babesiosis patients recover faster. About 33 adults with confirmed Babesia infection will receive either tafenoquine or a placebo, plus standard antibiotics. Researchers will track how quickly symptoms like fever and fatigue resolve and whether the infection is cleared.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tafenoquine (an antimalarial drug)
- What this could lead to
- If it works, this could provide a faster recovery and more effective treatment for hospitalized babesiosis patients.
- What could go wrong
- This is a small early-phase trial (33 people) testing a drug not yet approved for babesiosis. It may not show benefit or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BABESIOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tufts Medical Center
RECRUITINGBoston, Massachusetts, 02111, United States